about
The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritisManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisSecukinumab: A New Treatment Option for Psoriatic ArthritisUsing Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic DrugsValidity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study.Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatologyUS Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory studyPsoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT RegistrySecukinumab (AIN-457) for the treatment of Psoriasis.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.Secukinumab: a promising therapeutic option in spondyloarthritis.Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics.Quality of Life and Gastrointestinal Symptoms in Long-Term Treated Dermatitis Herpetiformis Patients: A Cross-Sectional Study in Finland.Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.The genetic basis of seborrhoeic dermatitis: a review.Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.Patient-relevant treatment goals in psoriasis.T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trialThe Patient-Reported Outcomes Thermometer–5-Item Scale (5T-PROs): Validation of a New Tool for the Quick Assessment of Overall Health Status in Painful Rheumatic Diseases
P2860
Q26821943-4FAAD695-03B9-4634-B508-5A9CC4F78F62Q27693878-57C0CFAF-EA20-4B64-BDFA-690D430FD073Q28066204-CC7520FF-1F03-47AE-9126-45FAD87CB3C3Q28547846-3A18B545-5826-40AC-BD09-4C2C140EE816Q33685731-AA1CC3D2-E4A2-4CAD-A02A-BC4185885B1FQ35896444-4AF65F25-5FEC-4D59-A0B2-F0F5DE288AF5Q36183841-9C78BF3E-B3B1-4765-8067-2AF62EC7A1B8Q36521222-11C7ACBB-B1BA-43A2-973B-017ECDB266D9Q37184479-93CEC93B-6279-4294-9554-1265C43301D1Q37208460-B0705423-18E5-44B4-8D25-248E21ADE748Q37308871-5E3B268A-776F-4D8A-9927-95398FDFBB40Q38372071-8A0A3722-79C5-4B0B-BEED-A4E5A6E233B7Q38662868-1E501DD6-1EDC-40E0-8A53-7316363BDED1Q38663614-904FA927-D3D5-486C-9B3B-01584B24EE56Q38903129-74C9A5EC-8427-4631-B9F3-A3FEF018A562Q39004045-99DD6BAF-155E-4064-862D-B46291D0B64BQ41060904-AE09905C-2E6C-4A59-A8EC-C0DB87B930C5Q41489371-BAD5600B-8246-4A2F-9435-19B9906A2576Q44332424-ECDB0EA9-3A63-489D-AA6A-5B02FCF7E151Q46129663-201A9A80-F4CF-45FA-A128-9ACE057876DFQ47387957-70F8FC97-893A-438E-AD5F-1BB1C37CDDBCQ47550260-BA98D4E0-C099-4959-8CBE-EE1E95B807A1Q47723896-F7B498FC-ADB8-461F-9DD2-966A46458A17Q47877368-18D86DC2-0322-4CF9-9CE1-B68E1FB84956Q55512008-0C321140-9CD0-4D5B-8E26-34784039ED13Q57169747-826A9EA4-C2CA-41AC-ADCF-A9D9C0F628CFQ58697954-069F9918-4D31-4418-8719-76671BECB4E9
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Burden of disease: psoriasis and psoriatic arthritis.
@en
type
label
Burden of disease: psoriasis and psoriatic arthritis.
@en
prefLabel
Burden of disease: psoriasis and psoriatic arthritis.
@en
P2860
P1476
Burden of disease: psoriasis and psoriatic arthritis.
@en
P2093
Alan Menter
Wolf-Henning Boehncke
P2860
P2888
P304
P356
10.1007/S40257-013-0032-X
P577
2013-10-01T00:00:00Z
P6179
1031896048